A systematic review and meta-analysis on the optimal treatment duration of checkpoint inhibitoRS in solid tumors: The OTHERS study-Reference-Cited by-同舟云学术

A systematic review and meta-analysis on the optimal treatment duration of checkpoint inhibitoRS in solid tumors: The OTHERS study

Published:2023-07 Issue: Volume:187 Page:104016
ISSN:1040-8428
Container-title:Critical Reviews in Oncology/Hematology
language:en
Short-container-title:Critical Reviews in Oncology/Hematology

Author:

Bogani Giorgio,Cinquini Michela,Signorelli Diego,Pizzutilo Elio G.,Romanò Rebecca,Bersanelli Melissa,Raggi Daniele,Alfieri Salvatore,Buti Sebastiano,Bertolini Federica,Bonomo Pierluigi,Marandino Laura,Rizzo Mimma,Monteforte Marta,Aiello Marco,Tralongo Antonio C.,Torri Valter,Di Donato Violante,Giannatempo Patrizia

Funder

AstraZeneca

AstraZeneca AG

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference76 articles.

1. UCLA Health. How Immunotherapy Became the Next Big Thing. Last accessed: December 19, 2021.

2. Effect of camrelizumab vs placebo added to chemotherapy on survival and progression-free survival in patients with advanced or metastatic esophageal squamous cell carcinoma: the ESCORT-1st randomized clinical trial;Luo;JAMA,2021

3. Considerations for treatment duration in responders to immune checkpoint inhibitors;Marron;J. Immunother. Cancer,2021

4. Immunotherapy discontinuation - how, and when? Data from melanoma as a paradigm;Robert;Nat. Rev. Clin. Oncol.,2020

5. Optimal duration of maintenance checkpoint inhibitor therapy in patients with advanced NSCLC;Shukla;JCO Oncol. Pract.,2021

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pathological insights into activin A: Molecular underpinnings and therapeutic prospects in various diseases;International Immunopharmacology;2024-09

2. Clinical and molecular features of platinum resistance in ovarian cancer;Critical Reviews in Oncology/Hematology;2024-09

3. Clinical applications and perspectives of immune checkpoint inhibitors in oral squamous cell carcinoma;Oncologie;2024-06-11

4. Banana-shaped survival curves of metastatic renal cell carcinoma treated with first-line immune-combinations, not just a matter of “palateau”;Human Vaccines & Immunotherapeutics;2024-05-17

5. Adding immunotherapy to first-line treatment of advanced and metastatic endometrial cancer;Annals of Oncology;2024-05